Target PharmaSolutions, Inc.
16
2
6
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 85/100
18.8%
3 terminated/withdrawn out of 16 trials
50.0%
-36.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
A Longitudinal Observational Study of the Natural History and Management of Patients With HCC
Role: lead
A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)
Role: lead
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
Role: lead
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
Role: lead
An Observational Study of Patients With Chronic Liver Disease
Role: lead
A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis
Role: lead
An Observational Study of Patients With Chronic Gastrointestinal Disease
Role: lead
An Observational Study of Patients With Chronic Kidney Disease
Role: lead
An Observational Study of Patients With Coronavirus Disease 2019
Role: lead
An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection
Role: lead
An Observational Study of Carbaglu® for the Treatment of MMA and PA in Adults and Pediatrics
Role: collaborator
A Study of Patients With Chronic Disease
Role: lead
An Observational Study of Patients With Autoimmune Disease
Role: lead
An Observational Study of Patients Living With Chronic Neurological Diseases
Role: lead
An Observational Study of Patients With Metabolic Syndrome and Related Conditions
Role: lead
Direct Acting Antiviral-Post Authorization Safety Study
Role: lead
All 16 trials loaded